Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus

Inclusion Criteria: * First or second (single or double) deceased or living donor kidney/kidney-pancreas transplant received at least six months previously; * Immunosuppressive therapy with tacrolimus and mycophenolate mofetil (MMF); Exclusion Criteria: Subjects expected to discontinue tacrolimus therapy; * Patients with thrombocytopenia (\<75,000/mm3), an absolute neutrophil count of \<1,500/mm3 and/or leukopenia (\<2,500/mm3), or anemia (hemoglobin \<6 g/dl) at baseline; * Patients experiencing an acute rejection in the previous two months, with inadequate (creatininemia \>2.5 mg/dL) or worsening renal function in the previous two months.